Tower Research Capital LLC TRC Buys 75,034 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Tower Research Capital LLC TRC boosted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 30.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 321,708 shares of the biopharmaceutical company’s stock after purchasing an additional 75,034 shares during the period. Tower Research Capital LLC TRC’s holdings in Pfizer were worth $8,535,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. PSI Advisors LLC boosted its stake in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. grew its stake in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton increased its position in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC lifted its stake in shares of Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 401 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.4 %

PFE opened at $22.13 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock’s 50 day moving average price is $24.88 and its 200-day moving average price is $26.17. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market cap of $125.50 billion, a price-to-earnings ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on PFE. UBS Group reduced their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.07.

Get Our Latest Stock Analysis on PFE

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles